212 related articles for article (PubMed ID: 1965445)
21. [Value of tumor markers in monitoring of cytotoxic treatment of non-small cell lung cancer].
Załeska M
Pneumonol Alergol Pol; 2003; 71(7-8):359-64. PubMed ID: 15052970
[No Abstract] [Full Text] [Related]
22. [Diagnostic value of combined detection of TPS, NSE and CEA in lung cancer].
Zheng H; He BF; Luo RC
Di Yi Jun Yi Da Xue Xue Bao; 2003 Feb; 23(2):165-6. PubMed ID: 12581971
[TBL] [Abstract][Full Text] [Related]
23. Values and limits of combined use of 4 tumor markers (CEA, TPA, NSE and SCC) in un-treated patients with lung cancer.
Cuomo A; Capra R; Greco S; Cacciani GC; Greco F; Franchini D; Bonelli P; Gavaruzzi G; Ugolotti G
Acta Biomed Ateneo Parmense; 1993; 64(5-6):171-84. PubMed ID: 7992555
[No Abstract] [Full Text] [Related]
24. The diagnostic and prognostic value of ProGRP in lung cancer.
Nisman B; Biran H; Ramu N; Heching N; Barak V; Peretz T
Anticancer Res; 2009 Nov; 29(11):4827-32. PubMed ID: 20032442
[TBL] [Abstract][Full Text] [Related]
25. Pro-gastrin-releasing peptide (ProGRP), neuron specific enolase (NSE), carcinoembryonic antigen (CEA) and cytokeratin 19-fragments (CYFRA 21-1) in patients with lung cancer in comparison to other lung diseases.
Schneider J; Philipp M; Velcovsky HG; Morr H; Katz N
Anticancer Res; 2003; 23(2A):885-93. PubMed ID: 12820318
[TBL] [Abstract][Full Text] [Related]
26. Prognostic markers for stage I non-small cell lung cancer.
Mizuguchi S; Nishiyama N
Lung Cancer; 2008 Feb; 59(2):274-5. PubMed ID: 18055061
[No Abstract] [Full Text] [Related]
27. Serum biomarkers facilitate the recognition of early- stage cancer and may guide the selection of surgical candidates: a study of carcinoembryonic antigen and tissue polypeptide antigen in patients with operable non-small cell lung cancer.
Buccheri G; Ferrigno D
J Thorac Cardiovasc Surg; 2001 Nov; 122(5):891-9. PubMed ID: 11689793
[TBL] [Abstract][Full Text] [Related]
28. [Value of combined detection of tumor markers for the prediction of small cell and non-small cell lung cancer].
Wu Y; Wu Y; Wang L; Qu L
Wei Sheng Yan Jiu; 2000 Jul; 29(4):213-5. PubMed ID: 12520921
[TBL] [Abstract][Full Text] [Related]
29. [Usefulness of monitoring levels of carcinoembryonic antigen, neuron-specific enolase and ferritin in serum of patients with small cell lung cancer for evaluating treatment outcome].
Szturmowicz M; Rogińska E; Roszkowski K; Kwiek S; Filipecki S; Rowińska-Zakrzewska E
Pneumonol Alergol Pol; 1993; 61(9-10):489-95. PubMed ID: 8111325
[TBL] [Abstract][Full Text] [Related]
30. Fuzzy logic-based tumor marker profiles including a new marker tumor M2-PK improved sensitivity to the detection of progression in lung cancer patients.
Schneider J; Peltri G; Bitterlich N; Neu K; Velcovsky HG; Morr H; Katz N; Eigenbrodt E
Anticancer Res; 2003; 23(2A):899-906. PubMed ID: 12820320
[TBL] [Abstract][Full Text] [Related]
31. [The diagnostic values of CA242 combining other tumor markers for lung cancer].
Zhang S; Ma Y; Yang X
Zhonghua Jie He He Hu Xi Za Zhi; 1999 May; 22(5):271-3. PubMed ID: 11775851
[TBL] [Abstract][Full Text] [Related]
32. [Tumor markers in lung cancer].
Niho S; Shinkai T
Gan To Kagaku Ryoho; 2001 Dec; 28(13):2089-93. PubMed ID: 11791391
[TBL] [Abstract][Full Text] [Related]
33. Usefulness of a multiple biomarker assay in bronchoalveolar lavage (BAL) and serum for the diagnosis of small cell lung cancer.
Nikliński J; Chyczewska E; Furman M; Kowal E; Laudanski J; Chyczewski L
Neoplasma; 1993; 40(5):305-8. PubMed ID: 8272160
[TBL] [Abstract][Full Text] [Related]
34. The prognostic value of both neuron-specific enolase (NSE) and Cyfra21-1 in small cell lung cancer.
Ando S; Suzuki M; Yamamoto N; Iida T; Kimura H
Anticancer Res; 2004; 24(3b):1941-6. PubMed ID: 15274381
[TBL] [Abstract][Full Text] [Related]
35. [Dimorphous cancer of the lung].
Briusov PG; Leonova VV
Vopr Onkol; 1997; 43(2):205-7. PubMed ID: 9214124
[TBL] [Abstract][Full Text] [Related]
36. [Relation between the level of TPS, NSE, CEA and beta2-mG in the serum and the biological behavior of small cell lung cancer].
Chen MS; Xu Y; Ma J; Wu CG; Hao XK; Lu BB; Liu T
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2007 Aug; 23(8):751-3. PubMed ID: 17618570
[TBL] [Abstract][Full Text] [Related]
37. Clinical evaluation of five tumor marker assay in patients with lung cancer.
Mizushima Y; Tsuji H; Izumi S; Hirata H; Kin Y; Kawasaki A; Matsui S; Yano S
Anticancer Res; 1991; 11(1):91-5. PubMed ID: 2018388
[TBL] [Abstract][Full Text] [Related]
38. Monitoring of therapy in inoperable lung cancer patients by measurement of CYFRA 21-1, TPA- TP CEA, and NSE.
Ebert W; Hoppe M; Muley T; Drings P
Anticancer Res; 1997; 17(4B):2875-8. PubMed ID: 9329552
[TBL] [Abstract][Full Text] [Related]
39. Utility of the serum tumor markers: CYFRA 21.1, carcinoembryonic antigen (CEA), and squamous cell carcinoma antigen (SCC) in squamous cell lung cancer.
Tas F; Aydiner A; Topuz E; Yasasever V; Karadeniz A; Saip P
J Exp Clin Cancer Res; 2000 Dec; 19(4):477-81. PubMed ID: 11277326
[TBL] [Abstract][Full Text] [Related]
40. Carcinoembryonic antigen, neuron-specific enolase and creatine kinase-BB as tumor markers for carcinoma of the lung.
Nikliński J; Furman M; Palynyczko Z; Laudański J; Bułatowicz J
Neoplasma; 1991; 38(6):645-51. PubMed ID: 1766488
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
